News - TP53 mutation - LARVOL VERI

19h

Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia (clinicaltrials.gov)

P1/2, N=20, Recruiting, University Hospital Tuebingen | Trial completion date: Mar 2027 --> Feb 2029 | Trial primary completion date: Mar 2027 --> Jul 2028

19 hours ago

Trial completion date • Trial primary completion date

TP53 (Tumor protein P53) • KMT2A (Lysine Methyltransferase 2A) • AFF1 (AF4/FMR2 Family Member 1) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1)

TP53 mutation • CD19 positive

Monjuvi (tafasitamab-cxix)

23h

Clinicopathological and molecular features of acquired cystic disease-associated renal cell carcinoma (PubMed, Zhonghua Bing Li Xue Za Zhi)

ACD-RCC is a rare renal cell carcinoma that occurs in patients with end-stage renal disease and has unique morphological features. It is often associated with favorable prognosis and alterations in genes related to the MTOR/TSC pathway or chromatin modification.

23 hours ago

Journal

ALK (Anaplastic lymphoma kinase) • TP53 (Tumor protein P53) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • KMT2C (Lysine Methyltransferase 2C) • TSC2 (TSC complex subunit 2) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • SDHB (Succinate Dehydrogenase Complex Iron Sulfur Subunit B) • TSC1 (TSC complex subunit 1) • SETD2 (SET Domain Containing 2, Histone Lysine Methyltransferase) • TFE3 (Transcription Factor Binding To IGHM Enhancer 3) • MME (Membrane Metalloendopeptidase) • KMT2B (Lysine Methyltransferase 2B) • GATA3 (GATA binding protein 3) • PAX8 (Paired box 8) • TFEB (Transcription Factor EB 2)

TP53 mutation

23h

Clinicopathological characteristics of anaplastic sarcoma of the kidney in children (PubMed, Zhonghua Bing Li Xue Za Zhi)

ASK in children is a rare DICER1-related tumor, with distinct histologic features and biological behavior. The differential diagnosis includes anaplastic Wilms tumor, clear cell sarcoma of the kidney, etc. Integration of clinical manifestations, histology, immunohistochemistry, and molecular studies may be required to render correct diagnosis.

23 hours ago

Journal

TP53 (Tumor protein P53) • DICER1 (Dicer 1 Ribonuclease III) • MYOD1 (Myogenic Differentiation 1)

TP53 mutation

ENY2 transcription and export complex 2 subunit deficiency induces nucleolar stress to inhibit tumor progression through NPM1/MDM2/p53-dependent and -independent responses. (PubMed, Cell Oncol (Dordr))

This study elucidated a previously unrecognized role of ENY2 in tumor growth, clarified the NPM1/MDM2/ p53-dependent mechanism of ENY2-mediated tumor cell growth suppression. We also provided a novel p53-independent RISC-IL11 nucleolar stress response pathway, which may provide a new target for the treatment of breast cancer.

1 day ago

Journal

TP53 (Tumor protein P53) • NPM1 (Nucleophosmin 1)

TP53 mutation

Prevalence and prognostic impact of HPV, EBV, and HIV in head and neck squamous cell carcinoma in the Brazilian Amazon cohort. (PubMed, Clin Transl Oncol)

TP53 and EGFR gene mutations were associated with more aggressive cancer phenotypes, leading to a 2.6-fold increase in the risk of death.

1 day ago

Journal

EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53)

TP53 mutation • EGFR mutation

Molecular-clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas. (PubMed, Int J Cancer)

Eighty-three percent of CR-NEC received first-line platinum-etoposide, while 98% of CR-AC patients received first-line fluorouracil-based chemotherapy. Metastatic CR-NEC and CR-AC are clinically distinct, with NEC demonstrating more aggressive features, limited treatment effect, and worse prognosis. Although they share important driver mutations, the underlying reason for their marked clinical differences remains unclear.

1 day ago

Journal

KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • APC (APC Regulator Of WNT Signaling Pathway)

TP53 mutation • KRAS mutation • BRAF mutation

5-fluorouracil • etoposide IV

A Clinical Guidance for the Management of Patients With Hepatoid Adenocarcinoma and A Case Series. (PubMed, Cancer Med)

In our patient cohort TP53 was the most frequently mutated gene (5 out of 8, 62.5%) and PD-L1 expression showed a positive score in 3 out of 6 patients (50%). However, only a few patients received immunotherapy (6 out of 14, 42.9%) suggesting that the numbers are too small to draw a conclusion about its efficacy in treating HAC.

1 day ago

Review • Journal • PD(L)-1 Biomarker • IO biomarker

TP53 (Tumor protein P53)

PD-L1 expression • TP53 mutation

A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) and BI 754111 or BI 907828 (Brigimadlin) in Combination With BI 754091 (Ezabenlimab) (clinicaltrials.gov)

P1, N=119, Active, not recruiting, Boehringer Ingelheim | Trial completion date: May 2026 --> Feb 2026

1 day ago

Trial completion date

TP53 (Tumor protein P53) • MDM2 (E3 ubiquitin protein ligase)

TP53 mutation • TP53 wild-type

brigimadlin (BI 907828) • ezabenlimab (BI 754091) • miptenalimab (BI 754111)

Single-Cell Lineage Trajectory Defines Cyclin-Dependent Kinase Inhibitor-Sensitive Cells-of-Origin in Esophageal Squamous Cell Carcinoma. (PubMed, Gastro Hep Adv)

Notably, CDK inhibitors markedly inhibit ESCC cell proliferation. This research delineates the potential cellular origins of ESCC and their key regulons, thereby pioneering a single-cell-derived therapeutic strategy that exposes vulnerabilities in tumor-initiating cells.

1 day ago

Preclinical • Journal

TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • TFAP2A (Transcription Factor AP-2 Alpha)

TP53 mutation

Pulmonary colloid adenocarcinoma mimicking lung abscess with concurrent KRAS and TP53 mutations: a case report. (PubMed, Front Med (Lausanne))

Failure to respond to standard antibiotic therapy and drainage should prompt consideration of an underlying malignancy. Surgical resection is essential for both definitive diagnosis and treatment.

1 day ago

Journal

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • CRP (C-reactive protein)

TP53 mutation • KRAS mutation

Case Report: CD19 CAR-T therapy induces durable remission in a pediatric patient with TP53-mutated, refractory Burkitt lymphoma: a 30-month follow-up. (PubMed, Front Oncol)

This case, among the youngest reported uses of commercial Axi-cel for BL, highlights the diagnostic complexity in adolescent lymphoma and demonstrates that CD19 CAR-T therapy can overcome TP53-associated chemoresistance in adolescent BL. It also suggests that integrating molecular profiling and immunotherapy may provide new strategies for managing high-risk, treatment-refractory cases in the adolescent and young adult population.

1 day ago

Journal • IO biomarker

TP53 (Tumor protein P53)

TP53 mutation

Yescarta (axicabtagene ciloleucel)

Research status and prospects of molecular pathological mechanisms and novel therapeutic targets of osteosarcoma: a systematic review. (PubMed, Front Oncol)

Future directions require integrating AI-driven imaging omics, spatiotemporal multi-omics, and mechanically adaptive biomaterials to establish a precision management system. This will advance osteosarcoma therapy from survival prolongation toward functional cure-defined as complete tumour eradication with physiological reconstruction of bone structure/function (e.g., restoring load-bearing/joint mobility), while preventing treatment-related disability, ultimately achieving oncologic cure with preserved quality of life.

1 day ago

Review • Journal • IO biomarker

TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • CTNNB1 (Catenin (cadherin-associated protein), beta 1)

TP53 mutation • RB1 mutation